5439602025-01-012025-03-315439602025-03-315439602024-03-315439602024-04-012025-03-315439602025-01-012025-03-31in-capmkt:OtherExpenses1Member5439602025-01-012025-03-31in-capmkt:OtherExpenses2Member5439602024-04-012025-03-31in-capmkt:OtherExpenses1Member5439602024-04-012025-03-31in-capmkt:OtherExpenses2Member5439602025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543960CONCORDBIONAINE338H01029Concord Biotech LimitedMain BoardEquity2024-04-012025-03-312025-05-292025-05-23INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2025-05-2917:00:002025-05-2918:30:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated429883800093840000439267800080268800010318500037910200038965700095500014616600071997900025417320001850946000018509460004181530001341700043157000001419376000000-1550400014038720007480100014786730001403872000014786730000104616000113.4213.420013.4213.42Notes to the statement of consolidated financial results for the quarter and year ended March 31 2025 <BR> <BR> 1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on May 29 2025. The Statutory Auditors of the company have carried out audit of the said results. <BR> <BR> 2. The figures for the quarter ended March 31 2025 and March 31 2024 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31 2024 and December 31 2023 which were subjected to limited review. <BR> <BR> 3. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard Ind AS 108 Operating Segment. <BR> <BR> 4. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 read together with Companies Indian Accounting Standards Rules 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI. <BR> <BR> 5. The board of directors have recommended final dividend of Rs.10.70 per fully paid up equity share of Rs. 1 each for financial year ended March 31 2025 on outstanding paid up share capital of the company as on date in its board meeting held on May 29 2025 subject to approval of shareholders at ensuing annual general meeting of the Company.2024-04-012025-03-31AuditedConsolidated12000869000444467000124453360002643126000559872000-1478670001389336000529300054373500024930870007486582000495875400004958754000118961400039496000122911000003729644000000-132210003716423000596890003776112000371642300003776112000010461600011802255900035.5235.520035.5235.52Power and Fuel293373000Others426606000Power and Fuel1122302000Others1370785000791805000050131000059610000228430005260000736500017989000000126007000305897000177660002056410008990093000239667200031654480005216515000904500027860004083190001536370008955750000113524220000020342515000104616000180225590001812717500001812717500000006298000629800028199000340217000003747140003811000595240001070874000113039800043656300015707720001131860005540000010126800001840626000002215340000203425150005293000-317134000-170787700007993900000-2193430000220891000050511000054373500001932100001661160000-129240000171010000-865800000-1340400000-94800000-141867300035400810000001094187000-7250002445169000008013707000869938900000000111172200019900000000000000316774000151171000000002994600000-15998650000000000005848700012791000915393000250500001496000-987680000-1423760000-1423760001514210009045000Re-measurement gain or loss on defined benefit plans2137000Income tax relating to re-measurement gain or loss on defined benefit plans-538000Fair value changes on equity investments through OCI97822000Income tax relating to fair value changes on equity investments through OCI-2462000074801000Re-measurement gain or loss on defined benefit plans-5698000Income tax relating to re-measurement gain or loss on defined benefit plans1434000Fair value changes on equity investments through OCI85462000Income tax relating to fair value changes on equity investments through OCI-215090005968900000007480100059689000AuditedtrueB S R and Co. LLPtrue2025-07-31